SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point of intense investor interest as the community awaits crucial Phase 3 data for its gene editing candidate and monitors the regulatory progress of its cardiac pipeline. With short interest levels remaining elevated, investors are actively debating the potential for a volatile move driven by upcoming clinical readouts and the possibility of a squeeze.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors react to a strategic partnership with OpenAI designed to accelerate drug discovery, while the community remains hyper-focused on the evolving competitive landscape against Eli Lilly's weight-loss pills. Conversations are dominated by debates over oral GLP-1 efficacy, long-term prescription velocity, and whether current technical levels signal a bottoming process or a value trap ahead of upcoming earnings.

APE fuels culture. Backed by the best club in the world and hundreds of thousands of holders worldwide, it’s the token for digital and IRL communities, builders, creators, collectors, gamers, and beyond.  APE is the native gas token of ApeChain and is available across multiple ecosystems including Ethereum, Arbitrum, Solana and HyperLiquid.z  ApeCoin's mission is is to supercharge its ecosystem by supporting high-quality builders &amp; reinforcing 3 core pillars: ApeChain, Bored Ape Yacht Club, and Otherside.

ApeCoin

ApeCoin is seeing a surge in investor attention and high-volume volatility, fueled by the launch of ApeChain and the influx of new on-chain projects. The community remains divided, with some traders highlighting the token's aggressive, flow-driven momentum while others express frustration over long-term price performance and historical dilution concerns.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors aggressively debate the company's long-term commercial potential, fueled by community speculation surrounding its collaboration with major industry players like Synopsys and Applied Materials. While some discuss a potential breakout driven by its Gate-All-Around transistor technology and perceived short-squeeze setups, skeptical voices emphasize the lack of material revenue and concerns over recurring share offerings.

Dumb SEND IT

$DSIT is generating significant buzz among community members who are positioning the token as a high-momentum weekend runner, with active discussions focused on breaking through previous market cap milestones. Investors are coordinating social media engagement and highlighting developer-led airdrops to build momentum, while comparisons to other meme coin cycles drive speculation about its growth potential.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is facing downward pressure following a series of insider share sales, which has sparked frustration among retail investors already concerned by the company's long-term capital efficiency and commercial ramp-up. Despite the negativity, the community remains divided between those calling for a strategic buyout or management change and long-term believers who are leveraging the dip to accumulate shares based on the company's extensive gene-editing pipeline and substantial cash position.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing significant market interest driven by heavy insider buying from the CEO and growing community speculation regarding potential strategic partnerships with major AI firms. Investors are closely monitoring price action as the stock attempts to reclaim key technical levels, balancing optimism for an ad-tech rebound against ongoing concerns about institutional short positioning and broader software sector volatility.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is capturing significant market attention following its public debut, with investors closely watching the nuclear developer's strategic partnerships with major tech giants like Amazon to fuel AI infrastructure demand. While the community is debating the stock's valuation and long-term viability, the conversation is largely driven by high initial demand and the broader narrative surrounding the role of small modular reactors in solving energy bottlenecks.

Chip

CHIP is capturing significant market attention following its simultaneous listing on major trading platforms, including Robinhood, fueling investor debate over whether the token is a high-utility AI infrastructure asset or a volatile pump-and-dump cycle. While many traders are focused on the rapid volume growth and long-term potential of its GPU-backed lending model, others caution against chasing the price amid community requests for updated branding and concerns over potential market manipulation.

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.

Compass Therapeutics Inc

Compass Therapeutics is seeing heightened investor attention as market participants track the upcoming Phase 2/3 clinical readout for tovecimig, a key bispecific antibody candidate for biliary tract cancer. The community is actively discussing the stock's binary event setup, weighing the potential for a breakthrough in a high-unmet-need oncology space against the inherent volatility typical of clinical-stage biotechs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Nuclear start-up X-Energy raised over $1 billion in its initial public offering.</li><li>Stock opened at $23, exceeding the initial target range of $16 to $19 per share.</li><li>Investor Ken Griffin is set to earn $300 million from a $100 million investment.</li></ul>Nuclear energy firm X-Energy (XE) surged as much as 31% in its debut, raising over $1 billion as investors bet surge in artificial intelligence usage will spur electricity demand, while strong commercial partnership deals provide added support.&nbsp;&nbsp;The stock opened at $30.11, after upsizing its initial price to $23 per share from the previously announced $16 - $19 per share range. The company raised more than $1 billion, making it the largest nuclear public offering on record.&nbsp;Nuclear power is garnering significant interest owing to a surge in electricity demand driven by rapid AI developments, which in turn demands more cloud storage and data center usage.&nbsp;&nbsp;Shares traded up 21% at 2.40 pm ET.&nbsp;<h2 class="st-heading-2">XE Business Model</h2>X-energy's core offering is the xe-100, an 80-megawatt, high-temperature gas-cooled reactor. This reactor type is notable for its high operating temperatures, which enable it to be used not only for electricity generation but also for industrial processes such as chemical production.&nbsp;Currently, all operational nuclear reactors in the U.S. are light water reactors.According to filings, the company doesn’t intend to own and operate nuclear plants, but would license its technology. The company will also manufacture and sell nuclear fuel, produced at its fabrication facility in Oak Ridge, Tennessee, where construction started in 2025.<h2 class="st-heading-2">XE Partnerships</h2>XE has made significant strides with its commercial partnerships with Amazon, Dow, and Centrica.&nbsp;Its primary commercial engine is&nbsp;Amazon, which anchored a $500 million funding round in late 2024 and holds a nearly 20% stake in the company. Amazon and XE are collaborating to deploy up to 5 GW of small modular reactor (SMR) capacity across the U.S. by 2039.&nbsp;Dow is nearing the construction phase of a four-unit Xe-100 plant at its Seadrift, Texas, manufacturing site—the first industrial-scale deployment of its kind in North America. Internationally, Centrica has emerged as a critical partner in the UK, recently signing a Memorandum of Understanding to build up to 12 reactors in Hartlepool.&nbsp;Ken Griffin, the founder of hedge fund Citadel, is set to gain about $300 million from a $100 million personal investment made 1.5 years ago, The Wall Street Journal reported.&nbsp;<h2 class="st-heading-2">Retail Take</h2>Retail sentiment on Stocktwits was ‘normal’ with ‘extremely high’ message volumes.One user mentioned taking small positions in IPOs.<stembedurl>https://stocktwits.com/TheBullishTrade/message/651327016</stembedurl>Another user expressed optimism, saying the stock could be a multibagger.&nbsp;<stembedurl>https://stocktwits.com/globaldaytraderzzz/message/651324660</stembedurl>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuclear Power Plant. Credit: Stock photo, Getty Images, Micha Pawlitzki

XE Stock Soars 31% In Debut As Commercial Partnerships Power Optimism

X-Energy’s partnerships with Amazon, Dow, and UK-based Centrica power positive sentiment. 

Equity

X-energy Announces Pricing of Upsized Initial Public Offering

X-energy, Inc. (X-energy), a leader in advanced nuclear reactor and fuel technology, today announced the pricing of its upsized initial public offering (IPO) of 44,254,659 shares of its Class A...

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

The market is buzzing over the massive trading debut of this Amazon-backed SMR developer which priced its IPO at $23 per share.

Traders are closely watching the firm as a strategic solution to the growing energy demands of data centers and artificial intelligence infrastructure.

Investors are weighing the newcomer's commercial potential against existing market players in the modular reactor space.

Debate is heating up over whether the company's $11.9 billion market cap is justified given its long-term roadmap and pre-revenue status.

Current Price	$29.20
Prev Close	$23.00
Open	$30.11
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	-$19.52
Price to Book	N/A
Revenue Per Employee	$122,719.91

XE
X-energy Inc

Feed

News

Sentiment

Fundamentals

Info

Latest XE News

XEX-energy Inc